ENERGY Study

Spring House, Pennsylvania, U.S. | August 24, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration...

STOCKHOLM, Sweden, June 11, 2026 Johnson & Johnson has reported positive pivotal Phase 2/3 results for IMAAVY® (nipocalimab-aahu) in...